No abstract

No abstract

Objective: Tolterodine tartrate (tolterodine) is used for treating overactive bladder (OAB) with symptoms of urinary frequency, urgency and leakage. Tolterodine is an antimuscarinic (anticholinergic) agent. It works by blocking a chemical that causes contractions of the bladder. Present work involved development of a novel drug delivery system of tolterodine intended to be taken once daily.Methods: Extended release (ER) pellets of tolterodine were prepared and optimized for in vitro drug release. Subsequently, these pellets were filled into a suitable sized capsule. The resulting capsules were evaluated for in vitro drug release. Optimized formulation was subjected to accelerated stability studies for 3 mo and was evaluated for description, average weight, assay and drug release.Results: The optimized ER capsule exhibited similar dissolution profile as that of the reference listed drug (RLD), with approximately 45%, 75% and more than 80% release in 3 h, 5 h and 7 h respectively. Accelerated stability studies indicated good physical and chemical stability of the formulation.Conclusion: ER formulation of tolterodine was optimized and can be used as once a day dosage, reducing the frequency of administration when compared with the immediate release formulation. The developed formulation exhibited similar behavior as that of reference formulation Detrol LA marketed in the US.

Benzimidazole and piperazines are the important pharmacophores in the structures of many antifungal compounds. Further, the phenylmethanone are also a unique class of compounds whose antifungal profile is not much exploited. So to exploit their antifungal potential we have selected these three combinations and framed the novel parent structure for our research work. In this study a novel series of benzimidazoles derivatives was synthesized by microwave irradiation and characterized by 1 H NMR, 13 C NMR, Infra Red (IR), and Mass Spectroscopy (MS), and by elemental analysis. The screening of compound for in vitro (turbidimetric method) antifungal activity against C.albicans revealed activity in many of the compounds as comparable to that of ketoconazole.

thiourea derivativesthiourea derivatives (benzene compounds) Q 0650 -151Synthesis, Antineoplastic and Anthelmintic Activities of N-Alkyloxycarbonyl-N'-(4-benzyloxy-2-nitrophenyl)thioureas as Prodrugs of (6-Benzyloxy-1H-benzimidazol-2-yl)carbamic Acid Ester.-Biological activities of the compounds (VI) and (VII) are evaluated against Ehrlich ascites carcinoma, ascaris and hymenolepsis infected animals. The methyl carbamates (VIa) and (VIIa) cause 90 to 100% elimination of ascaris and hymenolepsis species while the ethyl carbamates (VIb) and (VIIb) show poor activity. Fermentation of (VIa) with E. coli results in the formation of the cyclic product (VIIa). Compound (VIa) cannot be considered as a prodrug of (VIIa) as expected, because the former is not inert and is rather more active than the latter. -(BERA, T.; BELSARE, D. P.; Indian J.

This is a simple, economic, sensitive stability indicating RP-HPLC method for the simultaneous estimation of Salmeterol Xinafoate and Fluticasone Propionate in bulk and pharmaceutical Formulation. The method was carried out on Octa-decyl C 18 column (5 μm, 25 cm x 4.6 mm, i.d) using methanol: water in the ratio of 70:30 and pH of the mobile phase up to 3 was adjusted with OPA at a flow rate of 0.8 ml/min. The wavelength for Salmeterol Xinafoate and Fluticasone Propionate at 232 nm was found to be appropriate. The linearity range was obtained in the concentration range of 20 to 100 μg/ml for Salmeterol Xinafoate (SLM) and 20 to 100 μg/ml for Fluticasone (FLT) respectively. The retention time of Salmeterol Xinafoate and Fluticasone Propionate were found to be 3.59 and 6.3 min, respectively. The regression equation for SLM and FLT were found to be as y = 0.009x-0.003 and y = 0.009x-0.031 with correlation coefficient (R 2) 0.999 and 0.999, respectively. The developed method is found to be robust, accurate and sensitive which can be used for estimation of combination of Salmeterol Xinafoate and Fluticasone Propionate in pharmaceutical dosage forms. The method was applicable for the quality control of the mentioned drugs in raw material, bulk drug and pharmaceutical formulations.